Trazodone

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Trazodone is an antidepressant drug that has also been marketed under the brand names Desyrel, Oleptro, and Trialodine.[1] It belongs to the serotonin modulator class of antidepressants.[1]

There is virtually no evidence for the use of Trazodone to treat ME/CFS. In 2012 Solve ME/CFS Initiative contracted Biovista to use drug models to identify existing drugs that may be worth investigating for treatment. The results suggested Trazodone was worth considering.[2]

Notable studies[edit | edit source]

Media coverage[edit | edit source]

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]

  1. 1.0 1.1 "Trazodone: MedlinePlus Drug Information". medlineplus.gov. Retrieved January 9, 2019.
  2. Solve ME/CFS Initiative - Results of Biovista Work Released
  3. Kumar, Anil; Garg, Ruchika; Kumar, Puneet (October 2008), "Nitric oxide modulation mediates the protective effect of trazodone in a mouse model of chronic fatigue syndrome", Pharmacological reports: PR, 60 (5): 664–672, ISSN 1734-1140, PMID 19066412
  4. Morillas-Arques, Piedad; Rodriguez-Lopez, Carmen Ma; Molina-Barea, Rocio; Rico-Villademoros, Fernando; Calandre, Elena P. (September 10, 2010), "Trazodone for the treatment of fibromyalgia: an open-label, 12-week study", BMC musculoskeletal disorders, 11: 204, doi:10.1186/1471-2474-11-204, ISSN 1471-2474, PMC 2945951, PMID 20831796
  5. Calandre, Elena P.; Morillas-Arques, Piedad; Molina-Barea, Rocío; Rodriguez-Lopez, Carmen M.; Rico-Villademoros, Fernando (May 16, 2011), "Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study", BMC musculoskeletal disorders, 12: 95, doi:10.1186/1471-2474-12-95, ISSN 1471-2474, PMC 3112435, PMID 21575194